Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Summary of Shares Available for Issuance Under 2020 Plan

A summary of the shares available for issuance under the 2020 Plan is as follows:

	Number of Shares
Balance at December 31, 2022		1,002
Authorized		555
Granted/Awarded		(834	)
Cancelled		51
Balance at March 31, 2023		774

Summary of Option Award Activity

Option award activity under the 2020 Plan is set forth below:

	Options Outstanding
	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2022		1,202		$	6.91		8.7	$	—
Options granted		367		$	2.66
Options exercised		—		$	—
Options cancelled		(22	)	$	5.32
Outstanding at March 31, 2023		1,547		$	5.93		8.7	$	—
Vested and expected to vest at March 31, 2023		1,547		$	5.93		8.7	$	—
Vested and exercisable at March 31, 2023		617		$	7.17		8.2	$	—

Summary of Stock Options Outstanding and Vested

The following table summarizes information about stock options outstanding and vested as of December 31, 2022:

	Options Outstanding						Options Vested
Exercise Price	Options Outstanding		Weighted Average Remaining Contractual Term (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$2.65		349		9.8	$	2.65		—	$	—
$3.05 - $5.95		36		9.4	$	5.11		3	$	5.95
$6.04		421		8.7	$	6.04		125	$	6.04
$6.07 - $7.08		390		8.3	$	6.94		235	$	6.97
$7.13 - $8.62		351		8.0	$	8.01		254	$	7.92
		1,547		8.7	$	5.93		617	$	7.17

Summary of Fair Value of Stock Options was Estimated Using Assumptions

The fair value of stock options was estimated using the following assumptions for the three months ended March 31, 2023 and 2022:

	Three Months Ended March 31,
	2023	2022
Risk-free interest rate	3.5 - 4.2%	1.5 - 1.6%
Expected term (years)	6	6
Expected volatility	70%	70%
Dividends	0.0%	0.0%

Summary of Total Stock-Based Compensation Expense Recognized

The following table sets forth the total stock-based compensation expense recognized under the 2020 Plan and the 2020 ESPP in the Company's condensed statements of operations:

	Three Months Ended March 31,
	2023		2022
Cost of revenue – product	$	83	$	52
Cost of revenue – service		46		30
Selling, general and administrative expenses		1,426		1,377
Research and development expenses		171		148
Total	$	1,726	$	1,607

Summary of Unrecognized Stock-based Compensation Expense Expected to be Amortized

Total unrecognized stock-based compensation expense is expected to be amortized as follows:

Fiscal Year	Amount
2023	$	3,150
2024		1,681
2025		873
2026		159
2027		5
Thereafter		—
Total unrecognized stock-based compensation expense	$	5,868

Restricted Stock Awards

Summary of Restricted Stock Award Activity

Restricted stock award activity under the 2020 Plan is set forth below:

	Restricted Stock Awards Outstanding
	Number of Units			Weighted Average Grant Date Fair Value Per Share
Non-vested at December 31, 2022		622		$	10.29
Restricted stock awards granted		—		$	—
Restricted stock awards vested		(237	)	$	10.20
Restricted stock awards cancelled		(5	)	$	10.81
Non-vested at March 31, 2023		380		$	10.34

Restricted Stock Units

Summary of Restricted Stock Award Activity

Restricted stock unit activity under the 2020 Plan is set forth below:

	Restricted Stock Units Outstanding
	Number of Units			Weighted Average Grant Date Fair Value Per Share
Non-vested at December 31, 2022		86		$	6.33
Restricted stock units granted		468		$	2.65
Restricted stock units vested		(15	)	$	6.04
Restricted stock units cancelled		(25	)	$	2.65
Non-vested at March 31, 2023		514		$	3.16